Evidence map›Paper›PMID 25344549›Full record

ArticleCirculation. Heart failure2015

Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.

Bishnu P Dhakal, Rajeev Malhotra, Ryan M Murphy, Paul P Pappagianopoulos, Aaron L Baggish, Rory B Weiner, Nicholas E Houstis, Aaron S Eisman, Stacyann S Hough, Gregory D Lewis

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Circulation. Heart failure, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07202000 (Double-blind, Prospective, Randomized, Placebo-controlled Trial to Assess if Activin Ligand-trap Biological Therapy Can Improve Exercise Capacity and Cognitive Function in Heart Failure With Preserved Ejection Fraction Compared to Placebo.), which is not on this map. Cited by 218 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed, 8 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07202000 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Double-blind, Prospective, Randomized, Placebo-controlled Trial to Assess if Activin Ligand-trap Biological Therapy Can Improve Exercise Capacity and Cognitive Function in Heart Failure With Preserved Ejection Fraction Compared to Placebo.

TypeinterventionalSponsorMassachusetts General HospitalRan2026 to 2027Enrolled48ConditionsHeart Failure With Preserved Ejection FractionArmsActivin ligand-trap biological therapy, Placebo, Normal Saline
3 · Its place in the literature

Who cites it

218 citing papers in PubMed, 8 syntheses or guidelines pooled it, 410 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Peak OESC heart failure · 2022
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Assessment of Exercise Intolerance and Evaluation for HFpEF: A Literature Review of Pathophysiology, Diagnosis, and Management.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  17. Article
  18. Observational
  19. Review
  20. Review

158 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Bishnu P DhakalFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Rajeev MalhotraFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Ryan M MurphyFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Paul P PappagianopoulosFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Aaron L BaggishFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Rory B WeinerFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Nicholas E HoustisFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Aaron S EismanFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Stacyann S HoughFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Gregory D LewisFrom the Cardiology Division (B.P.D., R.M., R.M.M., A.L.B., R.B.W., N.E.H., A.S.E, G.D.L.) and the Pulmonary and Critical Care Unit (P.P.P., S.S.H., G.D.L.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston. glewis@partners.org.
Massachusetts General Hospital · US

Funding

Metabolic Profiling of Acute Myocardial Injury in HumansK23HL091106 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LEWIS, GREGORY DYER · 2008 to 2012
$711k
PITCH HF Right Ventricular Pulmonary Vascular Reserve Ancillary StudyR01HL119154 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LEWIS, GREGORY DYER · 2013 to 2013
$304k
NHLBI NIH HHS K23 HL091106NHLBI NIH HHS R01 HL119154
6 · The paper itself

Abstract

backgroundExercise capacity as measured by peak oxygen uptake (Vo2) is similarly impaired in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). However, characterization of how each component of Vo2 changes in response to incremental exercise in HFpEF versus HFrEF has not been previously defined. We hypothesized that abnormally low peripheral o2 extraction (arterio-mixed venous o2 content difference, [C(a-v)o2]) during exercise significantly contributes to impaired exercise capacity in HFpEF. METHODS AND

resultsWe performed maximum incremental cardiopulmonary exercise testing with invasive hemodynamic monitoring on 104 patients with symptomatic NYHA II to IV heart failure (HFpEF, n=48, peak Vo2=13.9±0.5 mL kg(-1) min(-1), mean±SEM, and HFrEF, n=56, peak Vo2=12.1±0.5 mL kg(-1) min(-1)) and 24 control subjects (peak Vo2 27.0±1.7 mL kg(-1) min(-1)). Peak exercise C(a-v)o2 was lower in HFpEF compared with HFrEF (11.5±0.27 versus 13.5±0.34 mL/dL, respectively, P<0.0001), despite no differences in age, hemoglobin level, peak respiratory exchange ratio, Cao2, or cardiac filling pressures. Peak C(a-v)o2 and peak heart rate emerged as the leading predictors of peak Vo2 in HFpEF. Impaired peripheral o2 extraction was the predominant limiting factor to exercise capacity in 40% of patients with HFpEF and was closely related to elevated systemic blood pressure during exercise (r=0.49, P=0.0005).

conclusionsIn the first study to directly measure C(a-v)o2 throughout exercise in HFpEF, HFrEF, and normals, we found that peak C(a-v)o2 was a major determinant of exercise capacity in HFpEF. The important functional limitation imposed by impaired o2 extraction may reflect intrinsic abnormalities in skeletal muscle or peripheral microvascular function, and represents a potential target for therapeutic intervention.

Indexed as

AgedExerciseExercise ToleranceFemaleHeart FailureHeart RateHumansMaleMiddle AgedMuscle, SkeletalOxygen ConsumptionPulmonary Gas ExchangeStroke Volumediastoleexerciseheart failure

Identifiers

PMID25344549
PMCPMC5771713
OpenAlexW2139605571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.